The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
This follows a similar move the FTC made in November involving 100 patents filed by pharma companies. The latest spate of “junk patent” listings include medicines for diabetes, asthma, COPD, and ...
disputing the accuracy of some 300 patent listings in the Food and Drug Administration’s so-called “Orange Book.” The crackdown, which comes six months after FTC challenged 10 pharma majors in a ...
In a warning letter sent to several drugmakers, including Ozempic's Denmark-based manufacturer Novo Nordisk, the FTC announced that it plans to challenge so-called "junk patents" that keep the ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...